DE69433160D1 - Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region - Google Patents

Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region

Info

Publication number
DE69433160D1
DE69433160D1 DE69433160T DE69433160T DE69433160D1 DE 69433160 D1 DE69433160 D1 DE 69433160D1 DE 69433160 T DE69433160 T DE 69433160T DE 69433160 T DE69433160 T DE 69433160T DE 69433160 D1 DE69433160 D1 DE 69433160D1
Authority
DE
Germany
Prior art keywords
motif
region
virus
hcv
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69433160T
Other languages
English (en)
Other versions
DE69433160T2 (de
Inventor
J Weiner
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22037528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69433160(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69433160D1 publication Critical patent/DE69433160D1/de
Application granted granted Critical
Publication of DE69433160T2 publication Critical patent/DE69433160T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
DE69433160T 1993-05-12 1994-05-03 Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region Revoked DE69433160T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6169993A 1993-05-12 1993-05-12
US61699 1993-05-12
PCT/US1994/004853 WO1994026306A1 (en) 1993-05-12 1994-05-03 Conserved motif of hepatitis c virus e2/ns1 region

Publications (2)

Publication Number Publication Date
DE69433160D1 true DE69433160D1 (de) 2003-10-30
DE69433160T2 DE69433160T2 (de) 2004-07-08

Family

ID=22037528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433160T Revoked DE69433160T2 (de) 1993-05-12 1994-05-03 Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region

Country Status (7)

Country Link
US (6) US7098303B1 (de)
EP (2) EP0697888B1 (de)
JP (3) JPH08510240A (de)
AT (1) ATE249838T1 (de)
CA (1) CA2162557C (de)
DE (1) DE69433160T2 (de)
WO (1) WO1994026306A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433160T2 (de) * 1993-05-12 2004-07-08 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
DE19504302A1 (de) * 1995-02-09 1996-08-14 Boehringer Mannheim Gmbh Methode zur serologischen Typisierung mittels typspezifischer Antigene
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
KR970065713A (ko) * 1996-03-19 1997-10-13 성재갑 C형 간염 바이러스(일본형)의 분비형 외피 단백질 1 및 2
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
ATE555794T1 (de) * 2000-02-14 2012-05-15 Mitsubishi Tanabe Pharma Corp Heilmittel gegen hepatitis
WO2009021063A2 (en) * 2007-08-06 2009-02-12 The Regents Of The University Of California Composition and method of use for hcv immunization
US8314371B2 (en) 2008-11-06 2012-11-20 Applied Materials, Inc. Rapid thermal processing chamber with micro-positioning system
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146633A (en) 1973-05-07 2000-11-14 The Ohio State University Method for treatment of antigenically modified polypeptides
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
ZA814386B (en) * 1980-07-01 1982-07-28 Nat Res Dev Production of viral antigens
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
EP0116201B1 (de) 1983-01-12 1992-04-22 Chiron Corporation Sekretorische Expression in Eukaryoten
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE102250T1 (de) 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
BR8807310A (pt) 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
US5252459A (en) 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
JP2656995B2 (ja) * 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
AU638719B2 (en) 1989-05-18 1993-07-08 Novartis Vaccines And Diagnostics, Inc. Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5308750A (en) 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
SK285623B6 (sk) * 1990-11-08 2007-05-03 Chiron Corporation Spôsob produkcie asialoglykoproteínu hepatitis C vírusu
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
US5574132A (en) 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
RU2148587C1 (ru) 1991-06-24 2000-05-10 Чирон Корпорейшн Полипептид и способ его получения, реагент для иммуноанализа, способ определения присутствия антител и способ индукции иммунного ответа
RU2212899C2 (ru) 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
JP3177983B2 (ja) 1992-02-05 2001-06-18 ダイキン工業株式会社 ポリテトラフルオロエチレン成形用粉末
KR20030096423A (ko) 1992-03-06 2003-12-31 엔. 브이. 이노제네틱스 소시에떼아노님 면역학적으로 중요한 에피토프에 상응하는 펩티드의 측정방법 및 면역학적으로 중요한 에피토프에 상응하는 항체또는 비오티닐화된 펩티드의 측정 방법에 상기 펩티드를사용하는 방법, 상기 펩티드의 제조방법 및 상기 펩티드를함유하는 조성물
DE69433160T2 (de) * 1993-05-12 2004-07-08 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
EP0992581B2 (de) 1993-11-04 2011-05-25 Innogenetics N.V. Immunodominante menschliche T-Zell Epitope des Hepatitis C Virus
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
PT1354204E (pt) * 2000-06-15 2007-03-30 Novartis Vaccines & Diagnostic Ensaio de combinação dum antigénio/anticorpo para o hcv

Also Published As

Publication number Publication date
US20070014813A1 (en) 2007-01-18
EP1421951A3 (de) 2005-10-05
CA2162557A1 (en) 1994-11-24
EP0697888B1 (de) 2003-09-17
JPH08510240A (ja) 1996-10-29
US6692907B1 (en) 2004-02-17
US7252827B1 (en) 2007-08-07
US20030017156A1 (en) 2003-01-23
US7371386B2 (en) 2008-05-13
US7135185B1 (en) 2006-11-14
US7098303B1 (en) 2006-08-29
JP2005097319A (ja) 2005-04-14
JP2005325126A (ja) 2005-11-24
EP0697888A1 (de) 1996-02-28
ATE249838T1 (de) 2003-10-15
EP1421951A2 (de) 2004-05-26
WO1994026306A1 (en) 1994-11-24
DE69433160T2 (de) 2004-07-08
CA2162557C (en) 2004-09-28

Similar Documents

Publication Publication Date Title
DE69433160D1 (de) Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
SG50563A1 (en) New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
AU3844095A (en) New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
CA2032381A1 (en) Viral agent
DK0388232T3 (da) NANBV diagnostiske midler og vacciner
ATE224956T1 (de) Verfahren zur verstärkten expression von virusproteinen
CA2079105A1 (en) Hepatitis c virus protease
LU91396I2 (fr) "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
EP0342860A3 (de) Neues Protein, Sequenze mit enthaltendem Gene, Vektoren, Verfahren zur Herstellung und Verwendung
DK0551275T3 (da) Non-A non-B sekvenser
DE69901099T4 (de) Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
DK257887A (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
FI981381A (fi) Menetelmä HCV-polypeptidien valmistamiseksi

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US